Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine candidate is protective in macaques.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
23 May 2022
23 May 2022
Historique:
pubmed:
7
6
2022
medline:
7
6
2022
entrez:
6
6
2022
Statut:
epublish
Résumé
Pediatric SARS-CoV-2 vaccines are needed that elicit immunity directly in the airways, as well as systemically. Building on pediatric parainfluenza virus vaccines in clinical development, we generated a live-attenuated parainfluenza virus-vectored vaccine candidate expressing SARS-CoV-2 prefusion-stabilized spike (S) protein (B/HPIV3/S-6P) and evaluated its immunogenicity and protective efficacy in rhesus macaques. A single intranasal/intratracheal dose of B/HPIV3/S-6P induced strong S-specific airway mucosal IgA and IgG responses. High levels of S-specific antibodies were also induced in serum, which efficiently neutralized SARS-CoV-2 variants of concern. Furthermore, B/HPIV3/S-6P induced robust systemic and pulmonary S-specific CD4
Identifiants
pubmed: 35665011
doi: 10.1101/2022.05.21.492923
pmc: PMC9164439
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Commentaires et corrections
Type : UpdateIn